中國核建(601611.SH):總經理徐曉明辭職 由戴雄彪接任
格隆匯3月3日丨中國核建(601611.SH)宣佈,近日,因工作變化原因,公司董事徐曉明不再擔任公司董事職務,同時不再擔任公司董事會審計委員會委員、總經理職務。因參與公司限制性股票激勵計劃,徐曉明目前持有公司股票22.78萬股。
2021年3月3日,公司第三屆董事會第二十三次會議審議通過了《關於提名董事的議案》,董事會同意提名陳寶智、戴雄彪為第三屆董事會董事候選人,並將該議案提交公司2021年第一次臨時股東大會審議;同時,通過《關於聘任總經理的議案》,董事會同意聘任戴雄彪為公司新任總經理。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.